Retrospective analysis finds TP53 and RB1 alterations predict poorer outcomes in metastatic castration-resistant prostate cancer, suggesting a need for better prognostic markers.
BACKGROUND: Docetaxel remains a standard treatment for metastatic castration-resistant prostate cancer (mCRPC), yet reliable prognostic markers are lacking. TP53 and RB1, key tumor suppressor genes regulating cell-cycle control and genomic stability, have been linked to aggressive disease and lineage plasticity in advanced prostate cancer. We evaluated the prognostic impact of TP53 and/or RB1 alterations in mCRPC patients treated with docetaxel. METHODS: We retrospectively analyzed 125 mCRPC patients treated with docetaxel. Genetic alterations were assessed using the TruSight Oncology 500 v2 panel. Progression-free survival (PFS) and overall survival (OS) were analyzed according to TP53 and RB1 alteration status. PFS was also shorter in patients with TP53 or RB1 alterations. CONCLUSION: TP53 and RB1 alterations, particularly TP53/RB1 co-alteration, are associated with poor prognosis in mCRPC treated with docetaxel.
No takes yet. Share an insight, caveat, or question.
Heo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: